Power Law company profile

Endocyte

Biotech & Life Sciences · West Lafayette, United States · Founded 1996 · IPO 2011 Unicorn

Developing targeted therapies for the personalized treatment of cancer

Valuation

$2.10B

Market cap · 2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

8 investors on Endocyte's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 8 investors entered at this stage

Sanderling Ventures

Triathlon Medical Venture Partners

Purdue University

Midcap Financial

Silicon Valley Bank

Blue Chip Venture Company

CID Equity Partners

Twilight Venture Partners

Global footprint

Where Endocyte has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Patent intelligence

$54M patent portfolio · 20 active families

Estimated portfolio value

$54M

2.6% of market cap · 5.9× smaller than top peer Exact Sciences ($319M)

20 active patent families

Where Endocyte innovates OncologyCarcinosisMolecular biologyPharmaceutical drugPharmacology

Where Endocyte concentrates vs peers

Each axis is a top-10 topic across Endocyte and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Endocyte

An AI-synthesized read of the highest-engagement posts about Endocyte on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Endocyte on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles